Groundbreaking ABTECT Trial Results Presented by Abivax
Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) has announced an exciting advancement in the treatment of ulcerative colitis following the results of the pivotal ABTECT trial. This clinical-stage biotechnology company, dedicated to harnessing the body's natural mechanisms to regulate immune responses, has shared significant findings from their Phase 3 ABTECT trials, which target moderate-to-severely active ulcerative colitis.
Key Outcomes from the ABTECT Trials
The results from the Phase 3 ABTECT trials revealed that a 50 mg once-daily dose of obefazimod resulted in an impressive 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8. These results were not only consistent across both ABTECT 1 and 2 trials but also met all primary and key secondary endpoints, indicating strong efficacy.
Enrollment and Patient Demographics
A total of 1,272 patients participated in the ABTECT trials, with a significant portion representing a refractory patient population. Notably, 47% of the participants had previously experienced an inadequate response to advanced therapies, including 21% who had not responded to JAK inhibitor therapy. This highlights the challenges faced by these patients and underscores the importance of the trial's findings.
Safety and Tolerability Profile
Regarding safety, the obefazimod treatment was considered well tolerated by participants. No new safety signals emerged for either the 25 mg or 50 mg doses. The most commonly reported treatment-emergent adverse events (TEAEs) included headaches, with incidences of 6% in the placebo group, 16% for 25 mg, and 24.1% for the 50 mg group. Importantly, these headaches rarely led to study discontinuation. Nausea was also reported, with rates of 1.3% in the placebo group compared to 5% and 7.2% for the lower and higher doses, respectively.
Expert Commentary on the Findings
Bruce Sands, MD, a well-regarded Professor of Medicine at the Icahn School of Medicine at Mount Sinai, expressed the significance of these findings: "There is an urgent need for new therapies to treat ulcerative colitis that deliver durable efficacy, safety, and the simplicity of oral, once-daily dosing. The ABTECT Trials enrolled individuals with advanced diseases, including many who had failed multiple lines of advanced therapy. The refractory nature of this population underscores the significance of the results presented today."
Looking Ahead: Future Presentations and Discussions
Looking forward, Abivax is scheduled to present a second late-breaking abstract on its findings, continuing to build upon the momentum of these latest trial results. Management has organized a conference call to discuss both late-breaking abstracts in greater detail at 9:00 AM ET on the designated date. This will provide an opportunity for investors and analysts to gain deeper insights into the outcomes and implications of the research.
About Abivax
Established in France and the United States, Abivax is dedicated to transforming the landscape of treatments for chronic inflammatory diseases. Their lead asset, obefazimod (ABX464), is currently under investigation in Phase 3 trials aimed at improving the lives of those afflicted by moderately to severely active ulcerative colitis.
Contact Information
For more information, you can reach out to Patrick Malloy, SVP of Investor Relations at Abivax SA. You can contact him directly via email at patrick.malloy@abivax.com or by phone at +1 847 987 4878.
Frequently Asked Questions
What are the main results from the ABTECT trials?
The ABTECT trials showed a 16.4% placebo-adjusted clinical remission rate at Week 8 for the 50 mg dose, meeting all primary and secondary endpoints.
Who participated in the ABTECT trials?
The trials enrolled 1,272 patients, primarily those with refractory ulcerative colitis who had previously failed advanced therapies.
What safety profile was observed for obefazimod?
The treatment was well tolerated, with common side effects including headaches and nausea, mostly mild and rare in causing discontinuation.
What is the next step for Abivax following these results?
Abivax plans to present further data and will hold a conference call to discuss the findings with investors and analysts.
What is obefazimod used for?
Obefazimod is being developed to treat moderate-to-severe ulcerative colitis and has shown promising results in clinical trials.
